FIA
KZR

FNY Investment Advisers’s Kezar Life Sciences KZR Stock Holding History

FNY Investment Advisers’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$314K – 958
2025
Q4 		$314K Buy
+50,000
New +$292K 0.09% 179
2019
Q3 		– Sell
-149
Closed -$11K – 1029
2019
Q2 		$11K Buy
+149
New +$23.2K ﹤0.01% 601

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

FNY Investment Advisers's KZR Position: Q1 2026 in Review

FNY Investment Advisers sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 50,000 shares — an estimated $314K sold.

FNY Investment Advisers first reported a position in KZR in Q2 2019 and held it in 2 quarters. The position peaked at $314K in Q4 2025. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • FNY Investment Advisers reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 50,000 Kezar Life Sciences shares in Q1 2026, an estimated $314K.
  • FNY Investment Advisers first reported a position in Kezar Life Sciences in Q2 2019 and held it in 2 quarters.
  • FNY Investment Advisers's Kezar Life Sciences position peaked at $314K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.